CDH2 and metastatic malignant neoplasm in the lymph nodes: Targeting N-cadherin switching holds excellent potential for developing effective therapeutic interventions to prevent or treat lymph node metastasis, ultimately improving oral cancer patients’ survival rates and quality of life.